CTLA4 and melanoma: In patients with melanoma treated with anti–PD-1 and anti–CTLA-4, DNA-PK (PRKDC) transcript levels inversely correlated with CD8 and MHC-I transcript levels, whereas mutations in DNA-PK correlated with increased tumor mutation burden (TMB) and neoantigen load.